W
Walter M. Cronin
Researcher at University of Pittsburgh
Publications - 34
Citations - 12613
Walter M. Cronin is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 22, co-authored 34 publications receiving 12155 citations. Previous affiliations of Walter M. Cronin include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
TL;DR: Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
Journal ArticleDOI
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,James L. Wade,Richard G. Margolese,Scott M. Lippman,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Leslie G. Ford,V. Craig Jordan,Norman Wolmark +17 more
TL;DR: Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.
Journal ArticleDOI
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.
TL;DR: The findings continue to indicate that lumpectomy followed by breast irradiation is appropriate therapy for women with either negative or positive axillary nodes and breast tumors 4 cm or less in diameter.
Journal ArticleDOI
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher,Joseph P. Costantino,D. Lawrence Wickerham,Reena S. Cecchini,Walter M. Cronin,André Robidoux,Therese B. Bevers,Maureen T. Kavanah,James N. Atkins,Richard G. Margolese,Carolyn D. Runowicz,Joan James,Leslie G. Ford,Norman Wolmark,Norman Wolmark +14 more
TL;DR: Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer.
Journal ArticleDOI
Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
TL;DR: Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue.